The JAK1/2 inhibitor ruxolitinib showed promising results in clinical trials and caused recompartmentalization of CLL cells from tissues to peripheral blood, which may provide a rationale for combination therapy with venetoclax [55], as currently explored in the context of AML (NCT03874052). Here, JAK1 is linked to B-cell chronic lymphocytic leukemia.